|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
KIAA1199 was selected for further analysis based on consistent up-regulation in neoplasia, previous studies and its interest as an uncharacterized gene.
|
22276102 |
2012 |
|
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KIAA1199 was upregulated in invasive breast cancer specimens and inversely associated with patient survival rate.
|
23990668 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
KIAA1199 serves as a novel cell migration-promoting gene and plays a critical role in maintaining cancer mesenchymal status.
|
23990668 |
2013 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
KIAA1199 serves as a novel cell migration-promoting gene and plays a critical role in maintaining cancer mesenchymal status.
|
23990668 |
2013 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KIAA1199 is a recently identified novel gene that is up-regulated in human cancer with poor survival.
|
24628760 |
2014 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
KIAA1199 is a recently identified novel gene that is up-regulated in human cancer with poor survival.
|
24628760 |
2014 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
KIAA1199 mRNA and protein was significantly overexpressed in breast tumor specimens and cell lines as compared with non-neoplastic breast tissues from large-scale microarray and studies of breast cancer cell lines and tumors.
|
24628760 |
2014 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
KIAA1199 mRNA and protein was significantly overexpressed in breast tumor specimens and cell lines as compared with non-neoplastic breast tissues from large-scale microarray and studies of breast cancer cell lines and tumors.
|
24628760 |
2014 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
KIAA1199 (also known as CEMIP or HYBID), a newly identified protein involved in hyaluronan degradation, has been suggested to play a critical role in cancer progression.
|
28012880 |
2017 |
|
Pancreatic carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer.
|
28179576 |
2017 |
|
Malignant neoplasm of pancreas
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer.
|
28179576 |
2017 |
|
Anaplasia
|
0.020 |
Biomarker
|
disease |
BEFREE |
KIAA1199: A novel regulator of MEK/ERK-induced Schwann cell dedifferentiation.
|
28699206 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Cell migration inducing hyaluronan binding protein (CEMIP) is a hyaluronic acid binding protein, the abnormal elevation of which is suggested as a contributor in the carcinogenesis of colorectal cancer (CRC).
|
29173982 |
2018 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Cell migration inducing hyaluronan binding protein (CEMIP) is a hyaluronic acid binding protein, the abnormal elevation of which is suggested as a contributor in the carcinogenesis of colorectal cancer (CRC).
|
29173982 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
KIAA1199 overexpression promoted CRC cell migration and invasion, which reversed the inhibition effect of miR-600 mimic on migration and invasion of CRC cells.
|
29776371 |
2018 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
KIAA1199 was upregulated in CRC tissues, and was negatively regulated by miR-600.
|
29776371 |
2018 |
|
Multiple Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KIAA1199 expression by activated astrocytes may explain the focal HA degradation observed during progression of MS and could represent a possible new therapeutic target.
|
30007349 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CEMIP expression in FB was downregulated in a glioma-associated oncogene homologue-dependent manner and CEMIP silencing in IPF FB reduced collagen production and attenuated cell proliferation and migration.Cumulatively, our approach indicates that pirfenidone exerts beneficial effects <i>via</i> its action on multiple pathways in both FB and other pulmonary cells, through its ability to control extracellular matrix architecture and inflammatory reactions.
|
30166321 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
KIAA1199 promotes invasion and migration in NSCLC via PI3K-Akt mediated EMT.
|
30478628 |
2019 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
KIAA1199 overexpression in HCC patients is associated with aberrant expression of EMT-associated markers and severe clinicopathological symptoms, and thus may function as a marker of poor prognosis in HCC.
|
30538502 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CEMIP (for "Cell migration-inducing protein" also called KIAA1199 and Hybid for "Hyaluronan-binding protein") expression is increased in cancers and described as a regulator of cell survival, growth and invasion.
|
30718510 |
2019 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
CEMIP is a cell migration-inducing protein that is closely associated with carcinogenesis.
|
30925458 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
CEMIP was elevated in tumour tissues and exosomes from patients with brain metastasis and predicted brain metastasis progression and patient survival.
|
31685984 |
2019 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIAA1199 may represent a novel target for GC pharmacotherapy.
|
31810922 |
2019 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIAA1199 may represent a novel target for GC pharmacotherapy.
|
31810922 |
2019 |